Oxy210, a novel inhibitor of hedgehog and TGF‐β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice

Oxy210, a novel inhibitor of hedgehog and TGF‐β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice

Abstract Aims Non‐alcoholic steatohepatitis (NASH) is associated with increased overall morbidity and mortality in non‐alcoholic fatty liver disease (NAFLD) patients. Liver fibrosis is the strongest prognostic factor for clinical outcomes, liver‐related mortality and liver transplantation. Currently...

Full description

Bibliographic Details
Main Authors: Simon T. Hui, Feng Wang, Frank Stappenbeck, Samuel W. French, Clara E. Magyar, Farhad Parhami, Aldons J. Lusis
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
cholesterol metabolism
liver fibrosis
non‐alcoholic Steatohepatitis
oxysterol
therapeutics
Online Access:https://doi.org/10.1002/edm2.296

Internet

https://doi.org/10.1002/edm2.296

Similar Items